We investigated the effects of the systemic administration of thymosin alpha1 plus relatively low doses of human recombinant interleukin-2 or very low doses of interferon alpha,beta in untreated and cyclophosphamide (CY)-treated DBA/2 mice challenged either subcutaneously or intravenously (i.v.) with Friend erythroleukemia cells (FLC). Both treatments resulted in the complete regression of subcutaneous tumor and cured a significative percentage of mice. They also increased the survival time of mice i.v. injected with large numbers of FLC. Neither immunotherapy alone nor CY, alone or in combination with single cytokines, produced similar effects. The antitumor action of these combined chemoimmunotherapy protocols seems to involve activation of the immune response since (a) a synergistic increase of the cytotoxicity of spleen cells was demonstrated in treated mice; (b) selective in vivo depletion of asialo-GM1, CD4, or CD8-positive cells abrogated this antitumor activity; and (c) a high lymphoid cell infiltration was found at the tumor site and in the livers of treated mice.

Garaci, E., Pica, F., Mastino, A., Palamara, A., Belardelli, F., & Favalli, C. (1993). Antitumor effect of thymosin alpha-1/interleukin-2 or thymosin alpha-1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic friend-erythroleukemia cells. JOURNAL OF IMMUNOTHERAPY WITH EMPHASIS ON TUMOR IMMUNOLOGY, 13(1), 7-17.

Antitumor effect of thymosin alpha-1/interleukin-2 or thymosin alpha-1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic friend-erythroleukemia cells

GARACI, ENRICO;PICA, FRANCESCA;FAVALLI, CARTESIO
1993

Abstract

We investigated the effects of the systemic administration of thymosin alpha1 plus relatively low doses of human recombinant interleukin-2 or very low doses of interferon alpha,beta in untreated and cyclophosphamide (CY)-treated DBA/2 mice challenged either subcutaneously or intravenously (i.v.) with Friend erythroleukemia cells (FLC). Both treatments resulted in the complete regression of subcutaneous tumor and cured a significative percentage of mice. They also increased the survival time of mice i.v. injected with large numbers of FLC. Neither immunotherapy alone nor CY, alone or in combination with single cytokines, produced similar effects. The antitumor action of these combined chemoimmunotherapy protocols seems to involve activation of the immune response since (a) a synergistic increase of the cytotoxicity of spleen cells was demonstrated in treated mice; (b) selective in vivo depletion of asialo-GM1, CD4, or CD8-positive cells abrogated this antitumor activity; and (c) a high lymphoid cell infiltration was found at the tumor site and in the livers of treated mice.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/07 - Microbiologia e Microbiologia Clinica
English
cyclophosphamide; thymosin alpha; interferon; interleukin-2; friend erythroleukemia cell tumor
Garaci, E., Pica, F., Mastino, A., Palamara, A., Belardelli, F., & Favalli, C. (1993). Antitumor effect of thymosin alpha-1/interleukin-2 or thymosin alpha-1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic friend-erythroleukemia cells. JOURNAL OF IMMUNOTHERAPY WITH EMPHASIS ON TUMOR IMMUNOLOGY, 13(1), 7-17.
Garaci, E; Pica, F; Mastino, A; Palamara, A; Belardelli, F; Favalli, C
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/51972
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact